NCT02740270View on ClinicalTrials.gov

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

July 22, 2016

Primary Completion Date

March 3, 2020

Study Completion Date

March 3, 2020

Conditions
Solid TumorsLymphomas
Interventions
DRUG

GWN323

DRUG

PDR001

Trial Locations (9)

10017

Novartis Investigative Site, New York

60637

Novartis Investigative Site, Chicago

77030

Novartis Investigative Site, Houston

169610

Novartis Investigative Site, Singapore

6423906

Novartis Investigative Site, Tel Aviv

02215

Novartis Investigative Site, Boston

M5G 2M9

Novartis Investigative Site, Toronto

277 8577

Novartis Investigative Site, Kashiwa

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY